Irinotecan: all 829 studies that test it
Page 4 of 9. Open to participants first (121), then studies with results posted, then the rest; newest registration first within each.
- Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer PatientsSuspendedNCT05062889Phase 2
- Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic AdenocarcinomaStatus unknownNCT05047991Phase 2
- Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing SarcomaWithdrawnNCT05042934Phase 1/2
- Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant ChemotherapyStatus unknownNCT05031975Phase 2
- Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.CompletedNCT05027386Phase 1/2
- SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Active, not recruitingNCT05022654Phase 2
- FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal CancerStatus unknownNCT05018182Phase 2
- Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract CancerTerminatedNCT05009953Phase 2
- Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal CancerStatus unknownNCT04929652Phase 1/2
- Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic CancerActive, not recruitingNCT04927780Phase 3
- c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRIStatus unknownNCT04833036Phase 2
- iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaCompletedNCT04808791Phase 2
- Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal CancerCompletedNCT04790448Phase 1/2
- How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer CervixStatus unknownNCT04789941Phase 2
- Docetaxel and Irinotecan in Gastric CancerCompletedNCT04770623Phase 2
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Active, not recruitingNCT04753879Phase 2
- Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT04752696Phase 2
- 131I-Omburtamab, in Recurrent Medulloblastoma and EpendymomaActive, not recruitingNCT04743661Phase 2
- Study of Irinotecan Liposome Injection in Patients With Advanced Breast CanceCompletedNCT04728035Phase 1
- Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)CompletedNCT04727853Phase 2
- Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric CancerActive, not recruitingNCT04725994Phase 1/2
- A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or CholangiocarcinomaStatus unknownNCT04668976Phase 2
- Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRCActive, not recruitingNCT04587128Phase 2
- Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid TumorsStatus unknownNCT04569916Phase 2
- A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor PatientsTerminatedNCT04492033Phase 1/2
- A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）Status unknownNCT04453930Phase 2
- FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)Status unknownNCT04442984Phase 2
- The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal CancerStatus unknownNCT04411537Phase 2
- The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal CancerStatus unknownNCT04411524Phase 2
- Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric CancerStatus unknownNCT04358354Phase 3
- Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic CancerActive, not recruitingNCT04340141Phase 3
- Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has SpreadActive, not recruitingNCT04233866Phase 2
- Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRCCompletedNCT04224415Phase 2
- NK Cells Infusions With Irinotecan, Temozolomide, and DinutuximabActive, not recruitingNCT04211675Phase 1/2
- Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG RegimenStatus unknownNCT04101929Phase 2
- A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and RhabdomyosarcomaCompletedNCT04095221Phase 1/2
- Phase I Trial HIPEC With Nal-irinotecanCompletedNCT04088786Phase 1
- SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma PatientsCompletedNCT04067115Phase 1/2
- Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver MetastasesWithdrawnNCT04037241Phase 2/3
- Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS MutationTerminatedNCT04034173Phase 2
- Second Line Treatment With Nal-IRI and S1 in Pancreatic CancerStatus unknownNCT03986294Phase 2
- Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 TypeStatus unknownNCT03963193Phase 2
- Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based TherapyCompletedNCT03883919Phase 1
- Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine CarcinomaCompletedNCT03837977Phase 2
- Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid TumorsCompletedNCT03810742Phase 1
- Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRCStatus unknownNCT03792269Phase 2
- FOLFIRINOX for 2nd-line Treatment of BTCCompletedNCT03778593Phase 2
- Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.Active, not recruitingNCT03773367Phase 2
- Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric CancerActive, not recruitingNCT03764553Phase 2
- MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnNCT03739801Phase 1/2
- Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal AdenocarcinomasTerminatedNCT03722108Phase 1/2
- Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell CarcinomaCompletedNCT03719924Phase 2
- Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or ChemoradiotherapyCompletedNCT03712397Phase 2
- First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRICompletedNCT03693677Phase 2
- Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung CancerStatus unknownNCT03613753Phase 2
- Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable CancerStatus unknownNCT03608046Phase 2
- A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI MalignanciesStatus unknownNCT03607643Phase 1/2
- Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal CancerStatus unknownNCT03567629Phase 2
- Irinotecan for Advanced and Metastatic Breast CancerStatus unknownNCT03562390Phase 2
- SGT-53 in Children With Recurrent or Progressive CNS MalignanciesWithdrawnNCT03554707Early Phase 1
- Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal CancerStatus unknownNCT03545711Phase 1/2
- A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic CancerStatus unknownNCT03528785Phase 2
- Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract CancerCompletedNCT03524508Phase 2
- A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLMCompletedNCT03493061Phase 2
- First-line Therapy in Metastatic PDACStatus unknownNCT03487016Phase 2
- 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line TherapyCompletedNCT03468335Phase 3
- mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First LineCompletedNCT03464968Phase 2
- A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination ChemotherapyCompletedNCT03454620Phase 1/2
- SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic CancerCompletedNCT03443492Phase 2
- Anlotinib and Irinotecan for Ewing SarcomaStatus unknownNCT03416517Phase 1/2
- The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic CancerStatus unknownNCT03403101Phase 2
- Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric AdenocarcinomaStatus unknownNCT03400592Phase 2
- Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell CarcinomaStatus unknownNCT03387904Phase 2
- Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal CancerWithdrawnNCT03380689Phase 1
- TAS102 in Combination With NAL-IRI in Advanced GI CancersActive, not recruitingNCT03368963Phase 1/2
- High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28Status unknownNCT03329183Phase 2
- Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer PatientsCompletedNCT03328884Phase 2
- S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic CancerStatus unknownNCT03316326Phase 2
- Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid TumorsCompletedNCT03295084Phase 1
- Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal CancerCompletedNCT03290937Phase 1
- Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell CarcinomaTerminatedNCT03251417Phase 2
- Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With CachexiaCompletedNCT03207724Phase 1
- Study of Chemoimmunotherapy for High-Risk NeuroblastomaActive, not recruitingNCT03189706Early Phase 1
- Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal CancerStatus unknownNCT03175016Phase 2/3
- A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic CancerStatus unknownNCT03167112Phase 2
- Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy NetworkCompletedNCT03164655Phase 2
- Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal CancerCompletedNCT03146377Phase 2
- PAZIT Study for Children and Young Adults With Relapsed or Refractory SarcomaCompletedNCT03139331Phase 1
- Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJAStatus unknownNCT03116555Phase 2
- FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective StudyWithdrawnNCT03110510Phase 2
- Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced CancerTerminatedNCT03096340Phase 1
- CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)CompletedNCT03086616Phase 1
- FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric CancerCompletedNCT03067792Phase 3
- Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGCStatus unknownNCT03061058Phase 3
- Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer PatientsStatus unknownNCT03053167Phase 2
- Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based TherapiesCompletedNCT03043547Phase 2
- Paediatric Hepatic International Tumour TrialActive, not recruitingNCT03017326Phase 3
- Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer PatientsCompletedNCT02980510Phase 2
- IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant SettingCompletedNCT02967289Phase 3
- Nordic Pancreatic Cancer Trial (NorPACT) - 1Active, not recruitingNCT02919787Phase 2/3